Shield raised $26.1m through a $20m term loan facility with SWK Holdings (unconditional) and $6.1m equity placing to fund several initiatives to drive improvement in gross-to-net (GTN) prices (including new field access team), fund the working capital needs (inventories and receivables) of the US growth story and repay the $5.7m AOP Health convertible loan. The interims and Q3 update clearly show the fruits of the Viatris collaboration, with covered lives increasing 20% to 123m (vs. 100m) and st ....

28 Sep 2023
Shield Therapeutics - $26.1m fundraise ($20.0m debt)/$6.1m equity)

Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Shield Therapeutics - $26.1m fundraise ($20.0m debt)/$6.1m equity)
Shield Therapeutics Plc (STX:LON) | 7.6 0 0.7% | Mkt Cap: 81.2m
- Published:
28 Sep 2023 -
Author:
Mark Brewer -
Pages:
21 -
Shield raised $26.1m through a $20m term loan facility with SWK Holdings (unconditional) and $6.1m equity placing to fund several initiatives to drive improvement in gross-to-net (GTN) prices (including new field access team), fund the working capital needs (inventories and receivables) of the US growth story and repay the $5.7m AOP Health convertible loan. The interims and Q3 update clearly show the fruits of the Viatris collaboration, with covered lives increasing 20% to 123m (vs. 100m) and st ....